Korro Bio, Inc.
About Korro Bio, Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $6.4M
- Net income
- -$117.3M
- Total assets
- $113.5M
- Market cap
- $154.6M
- Operating margin
- -1906.4%
- Net margin
- -1834.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $6.4M
- Operating expenses
- $128.2M
- Operating income
- -$121.9M
- Income tax
- $637.0K
- Net income
- -$117.3M
- EPS (basic)
- $-12.48
- EPS (diluted)
- $-12.48
Balance sheet
- Total assets
- $113.5M
- Current assets
- $82.4M
- Total liabilities
- $62.1M
- Current liabilities
- $11.9M
- Shareholders’ equity
- $51.4M
Cash flow
- Operating cash flow
- -$78.6M
- Investing cash flow
- $44.0M
- Financing cash flow
- $685.0K
- Net cash flow
- -$33.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $154.6M
- EPS (diluted)
- $-12.48
- Shares outstanding
- 14.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 6, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $117.3M in FY2025.
- Trading 79% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Korro Bio, Inc..
Write a review
News about Korro Bio, Inc.
News & sentiment via Polygon.io
